25I-NBOMe

Last updated
25I-NBOMe
2C-I-NBOMe-skeletal.svg
25I-NBOMe-spacefill.png
Clinical data
Other names2C-I-NBOMe; 25I; N-Bomb; Smiles; Wizard
Routes of
administration 		Buccal (sublabial), sublingual, insufflated, inhalation, intravenous, intramuscular, rectal
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Metabolism Extensive first-pass metabolism in the liver
Elimination half-life Unknown
Excretion Urine
Identifiers
  • 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C18H22INO3
Molar mass 427.282 g·mol−1
3D model (JSmol)
  • COC1=CC=CC=C1CNCCC2=CC(=C(C=C2OC)I)OC
  • InChI=1S/C18H22INO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3 Yes check.svgY
  • Key:ZFUOLNAKPBFDIJ-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

25I-NBOMe (2C-I-NBOMe, Cimbi-5, and also shortened to "25I"), also known as Smiles, or N-Bomb, is a novel synthetic psychoactive substance with strong hallucinogenic properties, synthesized in 2003 for research purposes. Since 2010, it has circulated in the recreational drug scene, often misrepresented as LSD.

Contents

25I was synthesized for biochemistry research to map the brain's usage of the type 2A serotonin receptor. A derivative of the substituted phenethylamine 2C-I family, it is the most well-known member of the 25-NB family. It was discovered in 2003 by chemist Ralf Heim at the Free University of Berlin, who published his findings in his PhD dissertation. [5] The compound was subsequently investigated by a team at Purdue University led by David Nichols. [6]

The carbon-11 labelled version of 25I-NBOMe, [11C]Cimbi-5, was synthesized and validated as a radiotracer for positron emission tomography (PET) in Copenhagen. [7] [8] Being the first 5-HT2A receptor full agonist PET radioligand, [11C]CIMBI-5 shows promise as a more functional marker of these receptors, particularly in their high affinity states. [7]

Street and media nicknames for this drug are: "N-Bomb", "Solaris", "Smiles", and "Wizard", although the drug is frequently fraudulently sold as LSD. [9] [10] [11]

Due to its physical effects and risk of overdose, there have been multiple deaths attributed to the drug. Its long term toxicity is unknown due to lack of existing research.

Recreational use

Although 25I-NBOMe was discovered in 2003, it did not emerge as a common recreational drug until 2010, when it was first sold by vendors specializing in the supply of designer drugs. [12] In a slang context, the name of the compound is often shortened to "25I" or is simply called "N-Bomb". [13] According to a 2014 survey, 25I-NBOMe was the most frequently used of the NBOMe series. [14] By 2013, case reports of 25I-NBOMe intoxication, with and without analytic confirmation of the drug in the body, were becoming increasingly common in the medical literature. [15]

25I-NBOMe is widely rumored to be orally inactive; however, apparent overdoses have occurred via oral administration. Common routes of administration include sublingual, buccal, and intranasal. [14] For sublingual and buccal administration, 25I-NBOMe is often applied to sheets of blotter paper of which small portions (tabs) are held in the mouth to allow absorption through the oral mucosa. [16] [17] There are reports of intravenous injection of 25I-NBOMe solution and smoking the drug in powdered form. [18] [19]

Due to its potency and much lower cost than so-called classical or traditional psychedelics, 25I-NBOMe blotters are frequently misrepresented as, or mistaken for LSD blotters. [20] Even small quantities of 25I-NBOMe can produce a large number of blotters. Vendors would import 25I-NBOMe in bulk (e.g., 1 kg containers) and resell individual doses for a considerable profit. [17]

Dosage

25I-NBOMe is potent, being active in sub-milligram doses. A common dose of the hydrochloride salt is 600–1,200  μg. The UK Advisory Council on the Misuse of Drugs states that a common dose is between 50 and 100 μg, [17] although other sources indicate that these figures are incorrect; Erowid tentatively suggests that the threshold dosage for humans is 50–250 μg, with a light dose between 200–600 μg, a common dose at 500–800 μg, and a strong dose at 700–1500 μg. [21]

At this level of potency, it is not possible to accurately measure a single dose of 25I-NBOMe powder without an analytical balance, and attempting to do so may put the user at significant risk of overdose. [17] There is a high risk of overdose due to the small margin between a high-dose and an over-dose, which is not a risk with the similar drug LSD. One study has shown that 25I-NBOMe blotters have 'hotspots' of the drug and the dosage is not evenly applied over the surface of the paper, which could lead to overdose. [22]

Effects

25I-NBOMe effects usually last 6–10 hours if taken sublingually, or buccally (between gum and cheek). [19] [ medical citation needed ] When it is insufflated (snorted), effects usually last 4–6 hours. [19] [ medical citation needed ]

25I-NBOMe has similar effects to LSD, though users report more negative effects while under the influence and more risk of harm following use as compared to the classical psychedelics. [14]

Case reports of seven British males who presented to an emergency room following analytically confirmed 25I-NBOMe intoxication suggest the following potential adverse effects: "tachycardia (n = 7), hypertension (4), agitation (6), aggression, visual and auditory hallucinations (6), seizures (3), hyperpyrexia (3), clonus (2), elevated white blood cell count (2), elevated creatine kinase (7), metabolic acidosis (3), and acute kidney injury (1)." [18]

25I-NBOMe can be consumed in liquid, powder or paper form and can be snorted, injected, mixed with food, or smoked, but sublingual administration is most common. [23]

Toxicity and harm potential

This section is an excerpt from 25-NB § Toxicity and harm potential.[ edit ]

NBOMe compounds are often associated with life-threatening toxicity and death. [24] [25] Studies on NBOMe family of compounds demonstrated that the substance exhibit neurotoxic and cardiotoxic activity. [26] Reports of autonomic dysfunction remains prevalent with NBOMe compounds, with most individuals experiencing sympathomimetic toxicity such as vasoconstriction, hypertension and tachycardia in addition to hallucinations. [27] [28] [29] [30] [31] Other symptoms of toxidrome include agitation or aggression, seizure, hyperthermia, diaphoresis, hypertonia, rhabdomyolysis, and death. [27] [31] [25] Researchers report that NBOMe intoxication frequently display signs of serotonin syndrome. [32] The likelihood of seizure is higher in NBOMes compared to other psychedelics. [26]

NBOMe and NBOHs are regularly sold as LSD in blotter papers, [25] [33] which have a bitter taste and different safety profiles. [27] [24] Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity. [24] Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD, [29] and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently". [27] While most fatalities are due to the physical effects of the drug, there have also been reports of death due to self-harm and suicide under the influence of the substance. [34] [35] [27]

Given limited documentation of NBOMe consumption, the long-term effects of the substance remain unknown. [27] NBOMe compounds are not active orally, [lower-alpha 1] and are usually taken sublingually. [37] : 3  When NBOMes are administered sublingually, numbness of the tongue and mouth followed by a metallic chemical taste was observed, and researchers describe this physical side effect as one of the main discriminants between NBOMe compounds and LSD. [38] [39] [40]

Neurotoxic and cardiotoxic actions

This section is an excerpt from 25-NB § Neurotoxic and cardiotoxic actions.[ edit ]

Many of the NBOMe compounds have high potency agonist activity at additional 5-HT receptors and prolonged activation of 5-HT2B can cause cardiac valvulopathy in high doses and chronic use. [25] [30] 5-HT2B receptors have been strongly implicated in causing drug-induced valvular heart disease. [41] [42] [43] The high affinity of NBOMe compounds for adrenergic α1 receptor has been reported to contribute to the stimulant-type cardiovascular effects. [30]

In vitro studies, 25C-NBOMe has been shown to exhibit cytotoxicity on neuronal cell lines SH-SY5Y, PC12, and SN471, and the compound was more potent than methamphetamine at reducing the visibility of the respective cells; the neurotoxicity of the compound involves activation of MAPK/ERK cascade and inhibition of Akt/PKB signaling pathway. [26] 25C-NBOMe, including the other derivative 25D-NBOMe, reduced the visibility of cardiomyocytes H9c2 cells, and both substances downregulated expression level of p21 (CDC24/RAC)-activated kinase 1 (PAK1), an enzyme with documented cardiac protective effects. [26]

Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in zebrafish, rats, and Artemia salina , a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the study also recommended further investigation of the drug's potential in damaging pregnant women and their fetus due to the substance's damaging effects to development. [44] [45]

Emergency treatment

This section is an excerpt from 25-NB § Emergency treatment.[ edit ]
At present, there are no specific antidotes for NBOMes, and all acute intoxication is managed by symptomatic treatments, such as administration of benzodiazepines, antipsychotic drugs, and antiarrhythmic agents, such as beta blockers; some emergency interventions are intended to specifically treat rhabdomyolysis, which may lead to critical complications such as metabolic acidosis and acute kidney injury. [26]

Attributed deaths

Reports of deaths and significant injuries have been attributed to the use of 25I-NBOMe, prompting some governments to control its possession, production, and sale. The website Erowid states that 25I-NBOMe is extremely potent and should not be snorted, and that the drug "appears to have led to several deaths in the past year." [20] Several non-fatal overdoses requiring prolonged hospitalization have also been reported. [17] [15] [18]

As of August 2015, 25I-NBOMe has reportedly led to at least 19 overdose deaths in the United States. [13] [46] In June 2012, two teens in Grand Forks, North Dakota and East Grand Forks, Minnesota fatally overdosed on a substance that was allegedly 25I-NBOMe, resulting in lengthy sentences for two of the parties involved and a Federal indictment against the Texas-based online vendor. [47] A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for "several hours" beforehand. It is unclear what other drugs he may have consumed, as autopsies generally do not test for the presence of research chemicals. [48] In January 2013, an 18-year-old in Scottsdale, Arizona, died after consuming 25I-NBOMe sold as LSD; a toxicology screening found no other drugs in the person's system. The drug is the suspected cause of death in another Scottsdale, Arizona, incident in April 2013. [17] It is also cited in the death of a 21-year-old woman in August 2013 [49] and the death of a 17-year-old in Minnesota in January 2014, [50] as well as the death of a 15-year old in Washington in September 2014. [51] In October 2015, a 20-year-old UCSB student from Isla Vista, California died of "acute hallucinogenic polysubstance intoxication" with an additional significant cause of death being "sharp force trauma of the upper extremity", according to a statement from Santa Barbara County Sheriff's office; the autopsy determined Sanchez was under the influence of two hallucinogenic drugs at the time of his death: ketamine and 25I-NBOMe. The noted sharp force trauma refers to a deep cut on Sanchez's right forearm, which was caused when he punched and broke a large residential window while suffering hallucinations. [52]

25I-NBOMe has been implicated in multiple deaths in Australia. In March 2012, a man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe. [53] A Sydney teenager jumped off a balcony to his death on June 5, 2013, while on 25I-NBOMe. [54]

25I-NBOMe has been linked to a major case on January 20, 2016, in Cork, Republic of Ireland, which left six teenagers hospitalized, one of whom later died. At least one of the teenagers suffered a cardiac arrest, according to reports, along with extreme internal bleeding. [55]

At least one suicide, and two attempted suicides leading to hospitalisation, have occurred while under the effects of 25I-NBOMe. [56]

Pharmacology

25I-NBOMe [57] [58] [ citation needed ]
ReceptorKd (nM)±
5-HT2A 0.044
5-HT2B 23173
5-HT2C 2
5-HT6 7312
μ-opioid 8214
κ-opioid 28850
H1 18935

25I-NBOMe acts as a highly potent full agonist for the human 5-HT2A receptor, [57] [59] with a dissociation constant (Kd) of 0.044 nM, making it some sixteen times the potency of 2C-I itself at this receptor. A radiolabelled form of 25I-NBOMe can be used for mapping the distribution of 5-HT2A receptors in the brain. [58]

25I-NBOMe induces a head-twitch response in mice which is blocked completely by a selective 5-HT2A antagonist, suggesting its psychedelic effects are mediated by 5-HT2A. This study suggested that 25I-NBOMe is approximately 14-fold more potent than 2C-I in-vivo. [60]

While in-vitro studies showed that N-benzyl derivatives of 2C-I were significantly increased in potency compared to 2C-I, the N-benzyl derivatives of the related compound DOI were inactive. [61]

25I-NBOMe also has weaker interactions with multiple other receptors. Kd values for interaction with the following targets were greater than 500 nM: 5-HT1A, D3, H2, 5-HT1D, α1A adrenergic, δ opioid, serotonin uptake transporter, 5-HT5A, 5-HT1B, D2, 5-HT7, D1, 5-HT3, 5-HT1E, D5, muscarinic M1-M5, H3, and the dopamine uptake transporter. [58]

Chemistry

Like other 2C-X-NBOMe molecules, 25I-NBOMe is a derivative of the 2C family of phenethylamines described by chemist Alexander Shulgin in his book PiHKAL. [17] [15] Specifically, 25I-NBOMe is an N-benzyl derivative of the phenethylamine molecule 2C-I, formed by adding a 2-methoxybenzyl (BnOMe) onto the nitrogen (N) of the phenethylamine backbone. This substitution significantly increases the potency of the molecule. [17]

Analogues

Analogues and derivatives of 2C-I:

25I-NB*:

N-(2C)-fentanyl:

Synthesis

25I-NBOMe is usually synthesised from 2C-I and 2-methoxybenzaldehyde, via reductive alkylation. It can be done stepwise by first making the imine and then reducing the formed imine with sodium borohydride, or by direct reaction with sodium triacetoxyborohydride. [5]

Society and culture

Australia

25I-NBOMe was explicitly scheduled in Queensland drug law in April 2012, and in New South Wales in October 2013, as were some related compounds such as 25B-NBOMe. The Australian federal government has no specific legislation concerning any of the N-benzyl phenethylamines. [63]

Canada

As of October 31, 2016; 25I-NBOMe is a controlled substance (Schedule III) in Canada. [64]

China

As of October 2015 25I-NBOMe is a controlled substance in China. [65]

European Union

In September 2014 the European Union implemented a ban of 25I-NBOMe in all its member states. [66]

Finland

25I-NBOMe is scheduled in government decree on narcotic substances, preparations and plants as of 2022 and is hence illegal to possess or use. [67]

Israel

Israel banned 25I-NBOMe in 2013. [68]

Russia

Russia was the first country to pass specific regulations on the NBOMe series. All drugs in the NBOMe series, including 25I-NBOMe, became illegal in Russia in October 2011. [68]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971 . [69]

United States

On Nov 15, 2013, the DEA added 25I-NBOMe (and 25C-, and 25B-NBOMe) to Schedule I using their emergency scheduling powers, making those NBOMe compounds "temporarily" in Schedule I for 2 years. [46] In November 2015, the temporary scheduling was extended for an additional year [70] while permanent scheduling was arranged. [71] 25I-NBOMe, 25B-NBOMe and 25C-NBOMe are currently Schedule 1 Substances according to 21 CFR 1308.11(d). [72]

Romania

In 2011, Romania banned all psychoactive substances. [73]

Serbia

25I-NBOMe was put on the list of prohibited substances in March 2015. [74]

Sweden

The Riksdag added 25I-NBOMe to Narcotic Drugs Punishments Act under Swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 1, 2013, published by Medical Products Agency (MPA) in regulation LVFS 2013:15 listed as 25I-NBOMe, and 2-(4-jodo-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin. [75]

Taiwan

Following the European rule from 2014, 25I-NBOMe was put in class 4 of prohibited substances. [76]

Brazil

All drugs in the NBOMe family, including 25I-NBOMe, are illegal.


United Arab Emirates

The UAE has a zero-tolerance policy for recreational use of drugs. Federal Law No. 14 of 1995 criminalises production, import, export, transport, buying, selling, possessing, storing of narcotic and psychotropic substances (Including 25i-NBOMe) unless done so as part of supervised and regulated medical or scientific activities in accordance with the applicable laws. The UAE police has dedicated departments to deal with drugs' issues. [77]

Notes

  1. ↑ The potency of N-benzylphenethylamines via buccal, sublingual, or nasal absorption is 50-100 greater (by weight) than oral route compared to the parent 2C-x compounds. [36] Researchers hypothesize the low oral metabolic stability of N-benzylphenethylamines is likely causing the low bioavailability on the oral route, although the metabolic profile of this compounds remains unpredictable; therefore researchers state that the fatalities linked to these substances may partly be explained by differences in the metabolism between individuals. [36]

Related Research Articles

<span class="mw-page-title-main">Serotonin receptor agonist</span> Neurotransmission-modulating substance

A serotonin receptor agonist is an agonist of one or more serotonin receptors. They activate serotonin receptors in a manner similar to that of serotonin, a neurotransmitter and hormone and the endogenous ligand of the serotonin receptors.

<span class="mw-page-title-main">25I-NBOH</span> Chemical compound

25I-NBOH is a derivative of the phenethylamine-derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University.

<span class="mw-page-title-main">25B-NBOMe</span> Chemical compound

25B-NBOMe is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT2A receptor. Duration of effects lasts about 3–10 hours, although the parent compound is rapidly cleared from the blood when used in the radiolabeled form in tracer doses. Recently, Custodio et al. (2019) evaluated the potential involvement of dysregulated dopaminergic system, neuroadaptation, and brain wave changes which may contribute to the rewarding and reinforcing properties of 25B-NBOMe in rodents.

<span class="mw-page-title-main">25I-NBF</span> Chemical compound

25I-NBF is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor, with bias towards the β-arrestin 2 coupled signalling pathway. It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).

<span class="mw-page-title-main">25TFM-NBOMe</span> Chemical compound

25TFM-NBOMe is a derivative of the phenethylamine hallucinogen 2C-TFM, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5-HT2A receptor, though its relative potency is disputed, with some studies finding it to be of lower potency than 25I-NBOMe, while others show it to be of similar or higher potency, possibly because of differences in the assay used. 2C-TFM-NB2OMe can be taken to produce psychedelic effects similar to 2C-I-NB2OMe and 2C-D-NB2OMe.

<span class="mw-page-title-main">25C-NBOMe</span> Psychedelic drug

25C-NBOMe is a psychedelic drug and derivative of the psychedelic phenethylamine 2C-C. 25C-NBOMe appeared on online vendor sites in 2010 but was not reported in the literature until 2011. It acts as a potent agonist of the 5-HT2A receptor, and has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET). Multiple deaths have occurred from usage of 25C-NBOMe due to the ease of accidental overdose. The long-term toxic effects of the drug have not been researched.

<span class="mw-page-title-main">25D-NBOMe</span> Chemical compound

25D-NBOMe is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe, which is a potent agonist at the 5-HT2A receptor. 25D-NBOMe has been sold as a street drug since 2010 and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe. It was banned as a Temporary Class Drug in the UK on 10 June 2013 after concerns about its recreational use.

<span class="mw-page-title-main">25C-NBOH</span> Chemical compound

25-C-NBOH is a derivative of the phenethylamine derived hallucinogen 2C-C which has been sold as a designer drug. It has similar serotonin receptor affinity to the better-known compound 25C-NBOMe.

<span class="mw-page-title-main">25CN-NBOMe</span> Chemical compound

25CN-NBOMe is a derivative of the phenethylamine 2C-CN. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5HT2A receptor.

<span class="mw-page-title-main">25N-NBOMe</span> Chemical compound

25N-NBOMe is a derivative of the hallucinogen 2C-N. The pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but it is believed to act in a similar manner to related compounds such as 25I-NBOMe and 25C-NBOMe, which are potent agonists at the 5HT2A receptor. 25N-NBOMe has been sold as a street drug and has only been described in the literature in terms of identification by forensic analysis.

<span class="mw-page-title-main">25E-NBOMe</span> Chemical compound

25E-NBOMe is a derivative of the phenethylamine 2C-E. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5-HT2A receptor. 25E-NBOMe has been sold as a drug and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe.

<span class="mw-page-title-main">25P-NBOMe</span> Chemical compound

25P-NBOMe is a derivative of the phenethylamine 2C-P. It acts in a similar manner to related compounds such as 25I-NBOMe, which are potent agonists at the 5-HT2A receptor. 25P-NBOMe has been sold as a drug and produces similar effects in humans to related compounds such as 25I-NBOMe and 25C-NBOMe.

<span class="mw-page-title-main">NBOMe-mescaline</span> Chemical compound

NBOMe-mescaline or mescaline-NBOMe is a synthetic substituted phenethylamine. It is a partial agonist of serotonin receptors with a 5-HT2A pKi originally reported as 7.3, though more modern techniques assayed it as 140nM at 5-HT2A and 640nM at 5-HT2C, making it one of the least potent compounds among the N-benzyl phenethylamines.

<span class="mw-page-title-main">25I-NB34MD</span> Derivative of the phenethylamine hallucinogen 2C-I

25I-NB34MD (NB34MD-2C-I) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a potent partial agonist for the human 5-HT2A receptor, and presumably has similar properties to 2C-I. It has a binding affinity of 0.67nM at the human 5-HT2A receptor, making it several times weaker than its positional isomer 25I-NBMD and a similar potency to 25I-NBF.

<span class="mw-page-title-main">25G-NBOMe</span> Chemical compound

25G-NBOMe (NBOMe-2C-G) is a derivative of the phenethylamine hallucinogen 2C-G, which acts as a highly potent agonist for the human 5-HT2A receptor.

<span class="mw-page-title-main">25H-NBOMe</span> Chemical compound

25H-NBOMe (NBOMe-2C-H) is a derivative of the phenethylamine hallucinogen 2C-H, which acts as a highly potent full agonist for the human 5-HT2A receptor.

<span class="mw-page-title-main">25I-NB3OMe</span> Chemical compound

25I-NB3OMe is a phenethylamine hallucinogen which acts as a partial agonist for the human 5-HT2A receptor. It is a derivative of 2C-I.

<span class="mw-page-title-main">25iP-NBOMe</span> Chemical compound

25iP-NBOMe is a derivative of the phenethylamine hallucinogen 2C-iP, which acts as a highly potent agonist for the human 5-HT2A receptor.

<span class="mw-page-title-main">25-NB</span> Family of serotonergic psychedelics

The 25-NB (25x-NBx) series, sometimes alternatively referred to as the NBOMe compounds, is a family of serotonergic psychedelics. They are substituted phenethylamines and were derived from the 2C family. They act as selective agonists of the serotonin 5-HT2A receptor. The 25-NB family is unique relative to other classes of psychedelics in that they are, generally speaking, extremely potent and relatively selective for the 5-HT2A receptor. Use of NBOMe series drugs has caused many deaths and hospitalisations since the drugs popularisation in the 2010s. This is primarily due to their high potency, unpredictable pharmacokinetics, and sellers passing off the compounds in the series as LSD.

<span class="mw-page-title-main">25E-NBOH</span> Chemical compound

25E-NBOH is a derivative of the phenethylamine derived hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent, but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper, as well as in Slovenia and France. It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT2A and 5-HT2C receptors.

References

  1. ↑ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
  2. ↑ "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". Canada Gazette. 4 May 2016. Archived from the original on 2016-08-31. Retrieved 2016-08-22.
  3. ↑ UK Home Office (2014). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Government. Archived from the original on 2014-12-04. Retrieved 2014-03-11.
  4. ↑ "Substance Details 25I-NBOMe". Archived from the original on 2024-01-23. Retrieved 2024-01-23.
  5. 1 2 Heim R (25 March 2003). "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts" (in German). diss.fu-berlin.de. Archived from the original on 2012-04-16. Retrieved 2013-05-10.
  6. ↑ Braden MR (2007). "Towards a biophysical understanding of hallucinogen action". Dissertation. Purdue University: 1–176. Archived from the original on 2016-09-19. Retrieved 2016-07-19.
  7. 1 2 Ettrup A, Palner M, Gillings N, Santini MA, Hansen M, Kornum BR, et al. (November 2010). "Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET". Journal of Nuclear Medicine. 51 (11): 1763–1770. doi: 10.2967/jnumed.109.074021 . PMID   20956470.
  8. ↑ Hansen M (16 December 2010). "Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain". Ph.D. Thesis. Det Farmaceutiske Fakultet, København. CiteSeerX   10.1.1.690.4529 .
  9. ↑ "Erowid 25I-NBOMe Vault". Archived from the original on 2016-06-30. Retrieved 2016-06-28.
  10. ↑ Vanderbilt University Medical Center (9 April 2015). "Poison center warns against designer drug 'N-bomb'". ScienceDaily. Archived from the original on 9 May 2016. Retrieved 14 April 2016.
  11. ↑ Mackin, Teresa (October 9, 2012). Dangerous synthetic drug making its way across the country. Archived October 31, 2012, at the Wayback Machine WISH-TV
  12. ↑ Morgans J (2017-02-08). "Everything We Know About NBOMe and Why it's Killing People". Vice. Archived from the original on 2019-07-24. Retrieved 2019-07-23.
  13. 1 2 Hastings D (May 6, 2013). "New drug N-bomb hits the street, terrifying parents, troubling cops". New York Daily News. Archived from the original on 10 May 2013. Retrieved 7 May 2013.
  14. 1 2 3 Lawn W, Barratt M, Williams M, Horne A, Winstock A (August 2014). "The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample". Journal of Psychopharmacology. 28 (8): 780–788. doi:10.1177/0269881114523866. PMID   24569095. S2CID   35219099.
  15. 1 2 3 Rose SR, Poklis JL, Poklis A (March 2013). "A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug". Clinical Toxicology. 51 (3): 174–177. doi:10.3109/15563650.2013.772191. PMC   4002208 . PMID   23473462.
  16. ↑ Poklis JL, Raso SA, Alford KN, Poklis A, Peace MR (October 2015). "Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper". Journal of Analytical Toxicology. 39 (8): 617–623. doi:10.1093/jat/bkv073. PMC   4570937 . PMID   26378135.
  17. 1 2 3 4 5 6 7 8 Iversen L (4 June 2013). "Temporary class drug order on benzofury and NBOMe compounds". Advisory Council on the Misuse of Drugs. Gov.Uk. Archived from the original on 24 August 2017. Retrieved 28 June 2016.
  18. 1 2 3 Hill SL, Doris T, Gurung S, Katebe S, Lomas A, Dunn M, et al. (July 2013). "Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series". Clinical Toxicology. 51 (6): 487–492. doi:10.3109/15563650.2013.802795. PMID   23731373. S2CID   41259282.
  19. 1 2 3 "2C-I-NBOMe (25I) Effects". Erowid. Archived from the original on 2016-06-30. Retrieved 2016-06-28.
  20. 1 2 "25I-NBOMe". Erowid.
  21. ↑ "2C-I-NBOMe (25I) Dose". Erowid. Archived from the original on 2016-06-30. Retrieved 2016-06-28.
  22. ↑ Lützen E, Holtkamp M, Stamme I, Schmid R, Sperling M, Pütz M, Karst U (April 2020). "Multimodal imaging of hallucinogens 25C- and 25I-NBOMe on blotter papers". Drug Testing and Analysis. 12 (4): 465–471. doi: 10.1002/dta.2751 . PMID   31846172. S2CID   209388281.
  23. ↑ Areas-Holmblad L (2016-12-11). "Using 'n-bomb' can kill you ~ Drug Addiction Now". Addiction Now | Substance Abuse, Drug Addiction and Recovery News Source. Archived from the original on 2020-09-13. Retrieved 2020-09-04.
  24. 1 2 3 Sean I, Joe R, Jennifer S, and Shaun G (28 March 2022). "A cluster of 25B-NBOH poisonings following exposure to powder sold as lysergic acid diethylamide (LSD)". Clinical Toxicology . 60 (8): 966–969. doi:10.1080/15563650.2022.2053150. PMID   35343858. S2CID   247764056.
  25. 1 2 3 4 Amy E, Katherine W, John R, Sonyoung K, Robert J, Aaron J (December 2018). "Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors". Biochemical Pharmacology. 158: 27–34. doi:10.1016/j.bcp.2018.09.024. PMC   6298744 . PMID   30261175.
  26. 1 2 3 4 5 Jolanta Z, Monika K, and Piotr A (26 February 2020). "NBOMes–Highly Potent and Toxic Alternatives of LSD". Frontiers in Neuroscience. 14: 78. doi: 10.3389/fnins.2020.00078 . PMC   7054380 . PMID   32174803.
  27. 1 2 3 4 5 6 Lipow M, Kaleem SZ, Espiridion E (30 March 2022). "NBOMe Toxicity and Fatalities: A Review of the Literature". Transformative Medicine. 1 (1): 12–18. doi: 10.54299/tmed/msot8578 . ISSN   2831-8978. S2CID   247888583.
  28. ↑ Micaela T, Sabrine B, Raffaella A, Giorgia C, Beatrice M, Tatiana B, Federica B, Giovanni S, Francesco B, Fabio G, Krystyna G, Matteo M (21 April 2022). "Effect of -NBOMe Compounds on Sensorimotor, Motor, and Prepulse Inhibition Responses in Mice in Comparison With the 2C Analogs and Lysergic Acid Diethylamide: From Preclinical Evidence to Forensic Implication in Driving Under the Influence of Drugs". Front Psychiatry. 13: 875722. doi: 10.3389/fpsyt.2022.875722 . PMC   9069068 . PMID   35530025.
  29. 1 2 Cristina M, Matteo M, Nicholas P, Maria C, Micaela T, Raffaella A, Maria L (12 December 2019). "Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe". Frontiers in Pharmacology. 10: 1406. doi: 10.3389/fphar.2019.01406 . PMC   6921684 . PMID   31915427.
  30. 1 2 3 Anna R, Dino L, Julia R, Daniele B, Marius H, Matthias L (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)". Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. ISSN   1873-7064. PMID   26318099. S2CID   10382311.
  31. 1 2 David W, Roumen S, Andrew C, Paul D (6 February 2015). "Prevalence of use and acute toxicity associated with the use of NBOMe drugs". Clinical Toxicology. 53 (2): 85–92. doi:10.3109/15563650.2015.1004179. PMID   25658166. S2CID   25752763.
  32. ↑ Humston C, Miketic R, Moon K, Ma P, Tobias J (2017-06-05). "Toxic Leukoencephalopathy in a Teenager Caused by the Recreational Ingestion of 25I-NBOMe: A Case Report and Review of Literature". Journal of Medical Cases. 8 (6): 174–179. doi: 10.14740/jmc2811w . ISSN   1923-4163.
  33. ↑ Justin P, Stephen R, Kylin A, Alphonse P, Michelle P (2015). "Analysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl) Methyl]Ethanamine Derivatives on Blotter Paper". Journal of Analytical Toxicology. 39 (8): 617–623. doi:10.1093/jat/bkv073. PMC   4570937 . PMID   26378135.
  34. ↑ Morini L, Bernini M, Vezzoli S, Restori M, Moretti M, Crenna S, et al. (October 2017). "Death after 25C-NBOMe and 25H-NBOMe consumption". Forensic Science International. 279: e1–e6. doi:10.1016/j.forsciint.2017.08.028. PMID   28893436.
  35. ↑ Byard RW, Cox M, Stockham P (November 2016). "Blunt Craniofacial Trauma as a Manifestation of Excited Delirium Caused by New Psychoactive Substances". Journal of Forensic Sciences. 61 (6): 1546–1548. doi:10.1111/1556-4029.13212. PMID   27723094. S2CID   4734566.
  36. 1 2 Sabastian LP, Christoffer B, Martin H, Martin AC, Jan K, Jesper LK (14 February 2014). "Correlating the Metabolic Stability of Psychedelic 5-HT2A Agonists with Anecdotal Reports of Human Oral Bioavailability". Neurochemical Research. 39 (10): 2018–2023. doi:10.1007/s11064-014-1253-y. PMID   24519542. S2CID   254857910.
  37. ↑ Adam H (18 January 2017). "Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens". Neuropharmacology of New Psychoactive Substances. Current Topics in Behavioral Neurosciences. Vol. 32. Springer. pp. 283–311. doi:10.1007/7854_2016_64. ISBN   978-3-319-52444-3. PMID   28097528.
  38. ↑ Boris D, Cristian C, Marcelo K, Edwar F, Bruce KC (August 2016). "Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC–MS". Journal of Chromatographic Science. 54 (7): 1153–1158. doi:10.1093/chromsci/bmw095. PMC   4941995 . PMID   27406128.
  39. ↑ Francesco SB, Ornella C, Gabriella A, Giuseppe V, Rita S, Flaminia BP, Eduardo C, Pierluigi S, Giovanni M, Guiseppe B, Fabrizio S (3 July 2014). "25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug". BioMed Research International. 2014: 734749. doi: 10.1155/2014/734749 . PMC   4106087 . PMID   25105138.
  40. ↑ Adam JP, Simon HT, Simon LH (September 2021). "Pharmacology and toxicology of N-Benzyl-phenylethylamines (25X-NBOMe) hallucinogens". Novel Psychoactive Substances: Classification, Pharmacology and Toxicology (2 ed.). Academic Press. pp. 279–300. doi:10.1016/B978-0-12-818788-3.00008-5. ISBN   978-0-12-818788-3. S2CID   240583877.
  41. ↑ Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL (Dec 2000). "Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications". Circulation. 102 (23): 2836–41. doi: 10.1161/01.CIR.102.23.2836 . PMID   11104741.
  42. ↑ Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (Jan 2000). "Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine". Molecular Pharmacology. 57 (1): 75–81. PMID   10617681.
  43. ↑ Roth BL (Jan 2007). "Drugs and valvular heart disease". The New England Journal of Medicine. 356 (1): 6–9. doi:10.1056/NEJMp068265. PMID   17202450.
  44. ↑ Xu P, Qiu Q, Li H, Yan S, Yang M, Naman CB, et al. (26 February 2019). "25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro". Neurotoxicity Research. 35 (4): 993–998. doi:10.1007/s12640-019-0012-x. PMID   30806983. S2CID   255763701.
  45. ↑ Álvarez-Alarcón N, Osorio-Méndez JJ, Ayala-Fajardo A, Garzón-Méndez WF, Garavito-Aguilar ZV (2021). "Zebrafish and Artemia salina in vivo evaluation of the recreational 25C-NBOMe drug demonstrates its high toxicity". Toxicology Reports. 8: 315–323. doi:10.1016/j.toxrep.2021.01.010. ISSN   2214-7500. PMC   7868744 . PMID   33598409.
  46. 1 2 "Three More Synthetic Drugs Become Illegal for at Least Two Years". United States Drug Enforcement Administration (DEA). 15 November 2013. Archived from the original on 15 August 2016. Retrieved 28 June 2016.
  47. ↑ Malisow C (13 March 2013). "Breaking Bad: Digital Drug Sales, Analog Drug Deaths". Houston Press. Archived from the original on 10 August 2016. Retrieved 28 June 2016.
  48. ↑ Martin N (1 November 2012). "21-year-old dies after one drop of new synthetic drug at Voodoo Fest". NOLA.com. Archived from the original on 3 November 2012. Retrieved 2 November 2012.
  49. ↑ "Fatal overdose case continues". Hibbing Daily Tribune. 5 March 2015.
  50. ↑ Giles K (28 April 2015). "After friend's OD death, teens get a reprieve". Star Tribune. Archived from the original on 11 June 2016. Retrieved 28 June 2016.
  51. ↑ Lowe LM, Peterson BL, Couper FJ (October 2015). "A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State". Journal of Analytical Toxicology. 39 (8): 668–671. doi: 10.1093/jat/bkv092 . PMID   26378143.
  52. ↑ Nicholas BB (16 November 2015). "Autopsy Results Released in Death of UCSB Student". Daily Nexus. Archived from the original on 23 March 2023.
  53. ↑ "New hallucinogenic drugs lead to Aussie man's death after running repeatedly into trees". TNT Magazine. United Kingdom. 12 September 2012. Archived from the original on 8 December 2022. Retrieved 23 August 2024.
  54. ↑ Davies N, Ralston L (2013-06-07). "'He wanted to fly': father says son made a fatal mistake". The Sydney Morning Herald. Archived from the original on 2022-06-22. Retrieved 2022-06-22.
  55. ↑ Feehan C (21 January 2016). "Powerful N-Bomb drug - responsible for spate of deaths internationally - responsible for hospitalisation of six in Cork". Irish Independent. Archived from the original on 12 April 2019. Retrieved 22 January 2016.
  56. ↑ Lipow M, Kaleem SZ, Espiridion E (2022-03-30). "NBOMe Toxicity and Fatalities: A Review of the Literature". Transformative Medicine. 1 (1): 12–18. doi: 10.54299/tmed/msot8578 . ISSN   2831-8978. S2CID   247888583. Archived from the original on 2023-02-01. Retrieved 2022-06-21.
  57. 1 2 Ettrup A, Hansen M, Santini MA, Paine J, Gillings N, Palner M, et al. (April 2011). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging. 38 (4): 681–693. doi:10.1007/s00259-010-1686-8. PMID   21174090. S2CID   12467684.
  58. 1 2 3 Nichols DE, Frescas SP, Chemel BR, Rehder KS, Zhong D, Lewin AH (June 2008). "High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand". Bioorganic & Medicinal Chemistry. 16 (11): 6116–6123. doi:10.1016/j.bmc.2008.04.050. PMC   2719953 . PMID   18468904.
  59. ↑ Silva ME, Heim R, Strasser A, Elz S, Dove S (January 2011). "Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor". Journal of Computer-Aided Molecular Design. 25 (1): 51–66. Bibcode:2011JCAMD..25...51S. CiteSeerX   10.1.1.688.2670 . doi:10.1007/s10822-010-9400-2. PMID   21088982. S2CID   3103050.
  60. ↑ Halberstadt AL, Geyer MA (February 2014). "Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response". Neuropharmacology. 77: 200–207. doi:10.1016/j.neuropharm.2013.08.025. PMC   3866097 . PMID   24012658.
  61. ↑ Braden MR, Parrish JC, Naylor JC, Nichols DE (December 2006). "Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists". Molecular Pharmacology. 70 (6): 1956–1964. doi:10.1124/mol.106.028720. PMID   17000863. S2CID   15840304.
  62. ↑ "Explore N-(2C-I)-Fentanyl | PiHKAL · info". isomerdesign.com.
  63. ↑ "Poisons Standard October 2015". Australian Government. October 2015. Archived from the original on 2016-06-02. Retrieved 2016-06-28.
  64. ↑ "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)". Canada Gazette. 4 May 2016. Archived from the original on 2016-08-31. Retrieved 2016-08-22.
  65. ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
  66. ↑ "Council Implementing Decision (2014/688/EU)". Official Journal of the European Union. 1 October 2014. Archived from the original on 3 August 2017. Retrieved 28 June 2016.
  67. ↑ "Archived copy". Archived from the original on 2023-11-29. Retrieved 2024-05-01.{{cite web}}: CS1 maint: archived copy as title (link)
  68. ↑ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.
  69. ↑ Drug Enforcement Administration (November 2015). "Schedules of Controlled Substances: Extension of Temporary Placement of Three Synthetic Phenethylamines in Schedule I. Final order" (PDF). Federal Register. 80 (219): 70657–70659. PMID   26567439. Archived (PDF) from the original on 2016-05-14. Retrieved 2016-06-28.
  70. ↑ "Schedules of Controlled Substances: Placement of Three Synthetic Phenethylamines Into Schedule I". Archived from the original on May 13, 2017. Retrieved May 15, 2017.
  71. ↑ "eCFR PART 1308—SCHEDULES OF CONTROLLED SUBSTANCES Schedule I." Archived from the original on 2020-09-13. Retrieved 2017-05-11.
  72. ↑ "Legea 194/2011 privind combaterea operatiunilor cu produse susceptibile de a avea efecte psihoactive, altele decat cele prevazute de acte normative in vigoare, republicata 2014". Drept OnLine. Archived from the original on 2020-09-01. Retrieved 2014-02-11.
  73. ↑ "Министарство здравља Републикe Србије". Archived from the original on 2017-12-28. Retrieved 2016-06-28.
  74. ↑ "Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika" [Regulations amending the Medical Products Agency's regulations (LVFS 2011: 10) on lists of drugs](PDF). Läkemedelsverkets (The Medical Products Agency) (in Swedish). 11 July 2013. Archived from the original (PDF) on 28 September 2013.
  75. ↑ "衛生福利部食品藥物管理署". 25 July 2016. Archived from the original on 7 October 2014. Retrieved 28 June 2016.
  76. ↑ "Drugs and controlled medicines | The Official Portal of the UAE Government". u.ae. Archived from the original on 2024-01-25. Retrieved 2024-01-25.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.